Mepivacaine Hydrochloride Accord Healthcare

Mepivacaine Hydrochloride, the active ingredient in Mepivacaine Hydrochloride Accord Healthcare, is a local anesthetic (amide type) presented as an injectable solution for epidural, infiltration, and perineural use. It provides reversible nerve block for dental, minor surgical and regional anesthesia procedures in adult patients.

GNH USA supplies Mepivacaine Hydrochloride Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mepivacaine Hydrochloride is a local anesthetic used to achieve reversible nerve block for various procedures.

- Dental procedures: provides short‑acting anesthesia for tooth extractions and restorative work. - Minor surgical procedures: enables infiltration anesthesia for skin incisions, suturing and biopsy. - Regional anesthesia: facilitates epidural or peripheral nerve block for orthopedic, obstetric or other regional techniques.

Mepivacaine Hydrochloride may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Injection site pain or burning sensation. - Transient dizziness or light‑headedness. - Nausea or mild vomiting. - Tingling or numbness beyond the intended area. - Temporary visual disturbances. - Mild headache.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Cardiovascular effects: hypotension, bradycardia, or arrhythmia. - Central nervous system toxicity: seizures, tremors, or loss of consciousness. - Methemoglobinemia. - Persistent numbness or motor weakness. - Severe respiratory depression.

When using Mepivacaine Hydrochloride, clinicians should consider several safety measures.

- Patient assessment: evaluate cardiac, hepatic and renal function before administration. - Allergy history: confirm no known hypersensitivity to amide‑type local anesthetics. - Dosage limits: adhere to recommended maximum doses to avoid systemic toxicity. - Monitoring: observe vital signs and neurological status during and after injection. - Drug interactions: avoid concurrent use with other sodium channel blockers. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Mepivacaine Hydrochloride can interact with other agents that affect cardiac conduction or central nervous system function.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may potentiate cardiotoxicity. - Other local anesthetics: increase risk of systemic toxicity. - Beta‑blockers: can exacerbate bradycardia.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines, opioids): may enhance sedation. - MAO inhibitors: potential for prolonged anesthetic effect. - Diuretics: may alter plasma protein binding and increase free drug levels.